



| Catalog No. | MS870039 |
|---|---|
| Description |
InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14) [RMP1-14] (MS870039) is a rat monoclonal antibody detecting Programmed cell death protein 1 in in vivo blocking of PD-1/PD-L signaling. Suitable for Mouse.
|
| Species reactivity | Mouse |
| Applications | in vivo blocking of PD-1/PD-L signaling |
| Host species | Rat |
| Isotype | IgG2a, kappa |
| Clone ID | RMP1-14 |
| Clonality | Monoclonal |
| Target | Programmed cell death protein 1, Protein PD-1, mPD-1, CD279, Pdcd1, Pd1 |
| Endotoxin level | <1 EU/mg |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q02242 |
| RRID | InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14) (abinScience Cat# MS870039, RRID:AB_3722748) |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Nishimura, H. et al. (1999) Immunity 11, 141-51. PMID: 10485649 2. Nishimura, H. et al. (2001) Science (New York, N.Y.) 291, 319-22. PMID: 11209085 3. Okazaki, T. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 13866-71. PMID: 11698646 4. Okazaki, T. et al. (2011) The Journal of experimental medicine 208, 395-407. PMID: 21300912 5. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 6. Latchman, Y. et al. (2001) Nature immunology 2, 261-8. PMID: 11224527 7. Lin, DY. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 3011-6. PMID: 18287011 8. Lázár-Molnár, E. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 10483-8. PMID: 18641123 9. Yokosuka, T. et al. (2012) The Journal of experimental medicine 209, 1201-17. PMID: 22641383 |
| Note | For research use only. |

SDS-PAGE for InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14).

Mice treatment with RMP1-14 significantly reduced tumor growth compared with the Rat IgG2a isotype control (RF533109), as shown by lower tumor volumes during the observation period.




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com




+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский